Why $110,000 of surgery cost one of our clients nothing.

The case

One of our clients (anonymised here, real per the file) developed a serious medical condition. The GP referred them to a specialist. The public-system wait for the specialist appointment was 4 months; the wait for the surgery itself, once accepted onto the surgical list, was another 10 months. Total from GP referral to surgery: 14 months.

The condition was not life-threatening on day one, but it was progressive. Quality of life would deteriorate over those 14 months. The household had two young children and one parent unable to work at full capacity for the duration.

The client also had private health insurance, taken out at our recommendation eight years earlier. The policy had a 'surgical and specialist' core module and a non-Pharmac drug benefit. Premium at that point was around $200 per month for the working-age adult.

What happened

With private cover in place, the specialist appointment was booked privately in week 2, paid by the insurer (less the per-claim co-payment of $50). The specialist confirmed the diagnosis and recommended surgery in week 3.

The surgical pre-approval went to the insurer in week 4. The insurer approved it in writing in week 5. The surgery was scheduled at a private hospital for week 7. Recovery was uneventful and the client was back to normal duties by week 11.

Total elapsed time from GP visit to back-to-normal: approximately 11 weeks.

The bill

Illustrative breakdown, real costs:

• Specialist consultation: ~$400
• Diagnostic imaging (MRI + ultrasound + bloods): ~$2,800
• Surgeon's fee: ~$28,000
• Anaesthetist's fee: ~$8,500
• Theatre fee: ~$22,000
• Private hospital admission (4 nights): ~$18,000
• Post-operative specialist follow-ups (3 visits): ~$1,200
• Pharmaceuticals (Pharmac-funded): ~$0 (free at point of use)
• Pharmaceuticals (non-Pharmac, claim against non-Pharmac drug benefit): ~$28,000
• Allied health (physiotherapy and rehab): ~$1,100

Total: approximately $110,000 [exact figure TBC pending Craig's review of the actual file].

The client paid the annual policy excess (~$500) plus a small co-payment on the initial specialist consult. Insurer paid the rest. Out of pocket for the whole episode: under $700.

What it would have looked like without cover

Two paths, neither great.

Path A: take the public wait. 14 months from referral to surgery. Quality of life deterioration over that period. Pressure on family finances if work capacity is reduced. Eventually surgery happens, free at point of use, and the household resumes normal. Total cash cost: zero, but 14 months of suboptimal life.

Path B: self-fund private. Same private pathway, same 7-week scheduling. Cash cost: $110,000, payable to the surgeon, anaesthetist, hospital and providers across the course of treatment. For a household without that liquid in savings, this would mean drawing down KiwiSaver early (if eligible) or borrowing against the house. Real for some households; not real for many.

The insurance premium for that 8 years was roughly $200 per month, or about $19,000 in total. The single claim recovered six times that. Most members will go years between meaningful claims. A small number have one claim that pays for decades of premiums.

Why this story matters

Two things sit underneath this case.

First, time is a real cost. 14 months of waiting for elective surgery is not a small inconvenience. It's quality of life lost, work capacity reduced, family stress accumulated. The financial value of avoiding that, for households who can afford the premium, is meaningful even before any single large claim.

Second, the non-Pharmac component is the often-undersold benefit. Pharmac is excellent at the medicines it funds. It does not fund several newer cancer therapies and specialist immune drugs that are standard of care in Australia, the UK and the US. A non-Pharmac benefit of $200,000 to $400,000 is the policy term that, in some cases, is the difference between standard global treatment and second-best. We don't lead with this when explaining health cover because it sounds alarmist, but when it matters, it matters a great deal.

What this case is not

This is not an argument that everyone should have health insurance, or that the public system is failing. The public system saves lives every day and handles all of the most expensive things (oncology, cardiac, intensive care) better than the private system because it concentrates expertise. For acute care, public is the right answer.

The case is about elective care, where the wait time is the variable that matters, and where private cover changes the wait time from years to weeks for a household that can afford the premium.

How we use cases like this in client conversations

We don't lead with case studies in a sales sense. We use them to make the abstract concrete. A 35-year-old in good health, with no family history of anything serious, often struggles to feel the value of health cover. A case like this, told plainly with real numbers (and the privacy of the client preserved), makes the question 'what would happen if this was you' real enough to think about properly.

For most working-age families with a mortgage and dependents, the answer is that some level of health cover is worth having. For older households with significant liquid assets, the answer is more nuanced. The conversation is worth having either way.